REJURAN healer

Product Overview

REJURAN Healer is a South Korean polynucleotide (PN) skin booster and tissue-restoration medical device developed and manufactured by PharmaResearch Co., Ltd. Formulated with 2% sodium polynucleotide (20 mg/mL), REJURAN Healer contains highly purified, salmon-derived DNA fragments processed using PharmaResearch's proprietary DOT™ (DNA Optimizing Technology). The product is intended for the temporary improvement of facial wrinkles in adults and is supplied as two 2 mL pre-filled syringes per box.

REJURAN Healer is the original facial polynucleotide formulation within the REJURAN medical aesthetics portfolio. It is commonly identified simply as REJURAN in the manufacturer's official product documentation.

Unlike conventional hyaluronic acid fillers, which primarily provide physical volume through a hydrated gel, REJURAN Healer contains purified polynucleotides derived from salmon DNA. Polynucleotides are long chains of nucleotide units associated with extracellular matrix interactions and biological processes relevant to tissue repair.

REJURAN Healer contains 20 mg of sodium polynucleotide per milliliter. Each 2 mL syringe therefore provides 40 mg of PN, while the standard two-syringe package contains a total of 80 mg.

The formulation does not contain added hyaluronic acid or lidocaine. These ingredients are incorporated into other members of the REJURAN product family, particularly REJURAN HB Plus.

PharmaResearch introduced REJURAN in South Korea in 2014. The product is classified as a Class IV tissue-restoration medical device under the South Korean regulatory system, with the documented intended purpose of temporarily improving facial wrinkles in adults.

This TEOSQUARE product page covers the original REJURAN Healer formulation only, providing professional buyers with information about its PN concentration, DOT™ technology, material characteristics, clinical evidence, packaging, storage requirements, and regulatory considerations.

Key Features

• 2% Polynucleotide Formulation: Contains 20 mg/mL sodium polynucleotide (PN), equivalent to 40 mg of PN per 2 mL syringe.
• Salmon-Derived DNA: Uses highly purified polynucleotides obtained from salmon-derived DNA through specialized extraction and purification processes.
• DOT™ Technology: Manufactured using PharmaResearch's proprietary DNA Optimizing Technology, developed to process and optimize marine-derived DNA materials.
• Facial Wrinkle Improvement: Registered in South Korea as a tissue-restoration medical device intended for temporary improvement of facial wrinkles in adults.
• PN-Based Skin Quality Approach: Commercially positioned for improving the appearance of facial skin texture, fine lines, and age-related skin changes.
• No Added HA or Lidocaine: Contains PN as its principal functional ingredient without the added hyaluronic acid and lidocaine found in certain other REJURAN formulations.
• 2 mL × 2 Syringes: The standard commercial package contains two pre-filled syringes, providing 4 mL of solution per box.
• Room-Temperature Storage: Manufacturer documentation specifies storage at 1–30°C with protection from light.
• South Korean Manufacturing: Developed and manufactured by PharmaResearch, a South Korean company specializing in regenerative medicine and medical aesthetics.

Composition & Specifications

REJURAN Healer contains highly purified sodium polynucleotide derived from salmon DNA.

Its documented PN concentration is 2%, equivalent to 20 mg/mL. The product is supplied as a transparent, viscous preparation in pre-filled syringes.

Sodium Polynucleotide (PN) — 20 mg/mL

Polynucleotides are biological macromolecules composed of repeating nucleotide units linked together through phosphodiester bonds.

DNA is naturally composed of polynucleotide chains that store and transmit genetic information.

REJURAN Healer uses highly purified DNA-derived polynucleotides obtained from salmon.

PharmaResearch processes the extracted DNA using its proprietary DOT™ technology to produce polynucleotide materials for medical applications.

REJURAN Healer contains sodium polynucleotide at a concentration of 20 mg/mL.

Each 2 mL syringe contains 40 mg of PN, and the complete two-syringe package contains 80 mg.

Research involving purified polynucleotides has investigated their effects on extracellular matrix characteristics, tissue hydration, and processes associated with skin repair.

However, the presence of polynucleotides does not independently establish a specific increase in collagen production, permanent tissue regeneration, or identical clinical results in every patient.

PN vs. PDRN

Polynucleotide (PN) and polydeoxyribonucleotide (PDRN) are related terms describing DNA-derived nucleotide polymers.

They are frequently used together in medical aesthetics marketing, but their commercial definitions and molecular-weight characteristics can differ.

REJURAN Healer is specifically formulated using sodium polynucleotide (PN).

It should not automatically be described as an interchangeable formulation of a PDRN pharmaceutical injection.

Differences in purification, molecular-weight distribution, formulation, and regulatory classification may influence the properties and intended applications of the finished product.

Hyaluronic Acid and Lidocaine

REJURAN Healer does not contain added hyaluronic acid or lidocaine.

Its principal functional ingredient is sodium polynucleotide at 2%.

This distinguishes the original Healer formulation from REJURAN HB Plus, which combines PN with HA and lidocaine.

The absence of lidocaine is relevant when evaluating product composition and patient comfort considerations.

REJURAN Healer contains 2% sodium polynucleotide (20 mg/mL). The product is not a hyaluronic acid filler and does not contain added lidocaine. Its composition should not be confused with REJURAN HB Plus or other REJURAN products.

DOT™ — DNA Optimizing Technology

One of REJURAN Healer's defining characteristics is PharmaResearch's proprietary DOT™ technology.

DOT™ stands for DNA Optimizing Technology, a patented manufacturing approach developed to process DNA extracted from salmon-derived biological materials.

Salmon-Derived DNA

PharmaResearch uses DNA obtained from salmon germ cells as a source material for its polynucleotide technology.

The extracted DNA undergoes manufacturing and purification processes before being incorporated into medical products.

The manufacturer emphasizes the characteristics of purified salmon-derived DNA as part of its regenerative medicine research.

DNA Processing and Optimization

DOT™ technology is designed to process and optimize DNA-derived materials for their intended biomedical applications.

PharmaResearch describes the process as involving specialized extraction, purification, and material optimization.

These manufacturing steps are intended to produce polynucleotide materials with controlled characteristics.

The specific molecular-weight distribution and analytical quality specifications should be confirmed using manufacturer-controlled technical documentation.

Purification and Material Quality

Purification is an important consideration when manufacturing medical products derived from biological raw materials.

Appropriate manufacturing controls are necessary to manage potential impurities, residual biological substances, and other material-quality characteristics.

DOT™ represents the manufacturer's proprietary technology for producing optimized polynucleotide materials.

However, the use of a patented manufacturing process does not independently establish superior clinical effectiveness or the complete absence of adverse reactions.

DOT™ is PharmaResearch's proprietary DNA Optimizing Technology. Claims concerning molecular purity, biological activity, or comparative clinical performance should be supported by appropriate product-specific analytical and clinical evidence.

How REJURAN Healer Works

REJURAN Healer is based on purified polynucleotides, which have been investigated for their interactions with biological tissues and extracellular matrix components.

Its material characteristics differ from those of conventional cross-linked hyaluronic acid fillers.

Polynucleotides and the Extracellular Matrix

The extracellular matrix is a complex network of biological molecules surrounding cells.

It contains structural proteins, glycosaminoglycans, and other components that contribute to tissue organization and mechanical properties.

Polynucleotide materials have been investigated for their potential interactions with the extracellular environment.

Their molecular structure and physicochemical characteristics provide the scientific basis for research involving tissue hydration and repair-associated processes.

Fibroblast-Associated Tissue Remodeling

Fibroblasts are connective tissue cells responsible for producing collagen and other extracellular matrix components.

Experimental research involving polynucleotide-based materials has investigated their relationship with fibroblast activity.

PharmaResearch commercially positions REJURAN Healer around the concept of supporting the skin's natural tissue-restoration processes.

However, these findings do not establish a guaranteed increase in dermal collagen, permanent skin regeneration, or a fixed amount of wrinkle improvement.

Hydration-Related Material Properties

Polynucleotide chains contain chemical groups capable of interacting with water.

These characteristics have been investigated in relation to the hydration and physical behavior of PN-based materials.

REJURAN Healer is commercially associated with improvements in the appearance of skin texture and hydration.

However, the extent of these effects depends on the finished formulation and clinical circumstances.

Temporary Facial Wrinkle Correction

The officially documented purpose of REJURAN in South Korea is the temporary improvement of facial wrinkles in adults.

Clinical studies involving the product have evaluated changes in facial wrinkles and other skin characteristics.

Treatment outcomes vary among individuals, and the available evidence does not establish a permanent correction of facial wrinkles.

Polynucleotide research provides a scientific basis for investigating tissue-restoration and skin-quality effects. The product's authorized purpose should be distinguished from broader biological claims that have not been established for every clinical application.

Clinical Evidence & Product Research

REJURAN has been investigated in clinical studies examining the use of purified polynucleotides for aesthetic skin applications.

These studies provide evidence concerning specific treatment conditions and measured outcomes. Their findings should not be generalized to all anatomical regions, treatment combinations, or patient populations.

Clinical Investigation of Facial Wrinkles

A randomized, double-blind clinical study published in 2014 evaluated a 20 mg/mL REJURAN polynucleotide formulation for the correction of crow's-feet wrinkles.

The study enrolled 72 participants and compared the PN formulation with a non-crosslinked hyaluronic acid preparation.

The investigators reported that REJURAN met the study's predefined non-inferiority criteria for the primary wrinkle-improvement outcome.

The study did not establish superior effectiveness across the evaluated clinical outcomes.

These findings support the investigation of PN-based materials for temporary facial wrinkle improvement within the study's defined conditions.

Research on Skin Hydration and Recovery

A prospective split-face study published in 2026 evaluated REJURAN PN injection as an adjunct to fractional needle radiofrequency treatment.

The study included 25 participants and assessed several skin parameters following combined treatment.

Compared with the control side, the PN-treated side showed greater improvements in certain measured wrinkle, pore, hydration, and skin-barrier parameters.

However, the study did not identify statistically significant between-side improvements in all evaluated outcomes, including dermal thickness and elasticity.

Because the investigation involved treatment in combination with radiofrequency, its results should not automatically be interpreted as evidence of identical benefits from REJURAN alone.

Limitations of Clinical Evidence

Clinical research involving REJURAN and other polynucleotide products has investigated outcomes including wrinkles, skin texture, hydration, and recovery after aesthetic procedures.

However, study designs, sample sizes, treatment combinations, follow-up periods, and evaluation methods differ.

The available evidence does not justify guaranteed claims of permanent collagen regeneration, scar elimination, pore reduction, or a fixed duration of treatment effects.

Clinical findings should be interpreted according to the specific formulation, patient population, treatment conditions, and measured outcomes. The approved intended use of REJURAN remains temporary improvement of facial wrinkles in adults.

REJURAN Healer vs. Other REJURAN Products

PharmaResearch offers several REJURAN medical aesthetics products with different formulations and commercial positioning.

REJURAN Healer should be distinguished from REJURAN i, REJURAN s, and REJURAN HB Plus.

REJURAN Healer

REJURAN Healer is the original 2% PN formulation supplied as two 2 mL syringes.

It is commercially positioned for general facial skin-quality concerns and temporary facial wrinkle improvement.

The documented formulation does not contain added HA or lidocaine.

REJURAN i

REJURAN i is a separate PN formulation with lower viscosity, commercially positioned for the delicate skin surrounding the eyes.

It contains 2% PN and is supplied as one 1 mL syringe.

Its formulation characteristics and packaging differ from those of the standard Healer product.

REJURAN s

REJURAN s is a higher-viscosity PN formulation commercially associated with scar-related aesthetic concerns.

It contains 2% PN and is supplied as one 1 mL syringe.

Its scar-oriented positioning should not be confused with the formally approved indication without consulting the applicable product labeling.

REJURAN HB Plus

REJURAN HB Plus is a separate formulation combining PN, hyaluronic acid, and lidocaine.

Its PN concentration is 1%, and it contains 0.3% lidocaine.

The inclusion of HA and lidocaine differentiates HB Plus from REJURAN Healer.

This page describes REJURAN Healer only. REJURAN i, s, and HB Plus are separate products. Their ingredient concentrations, packaging, storage conditions, and authorized indications should not be automatically applied to the original Healer formulation.

Packaging & Product Presentation

REJURAN Healer is supplied as a sterile, transparent PN preparation in pre-filled syringes.

The manufacturer's standard commercial presentation contains two 2 mL syringes, providing 4 mL of product per box.

2 mL Pre-Filled Syringes

Each REJURAN Healer syringe contains 2 mL of a 2% PN preparation.

The product is supplied in pre-filled form rather than as a lyophilized powder requiring reconstitution.

Its concentration remains 20 mg/mL throughout the documented presentation.

Two-Syringe Commercial Box

The standard manufacturer-documented package contains two syringes.

Commercial product brochures identify 33G × 4 mm needles. The exact needle quantity and accessory configuration should be confirmed from the original package supplied in the destination market.

Product Authentication

PharmaResearch has introduced product authentication features for REJURAN packaging, including QR-based identification and NFC technology.

The manufacturer introduced these features to help address counterfeit products and unauthorized international distribution.

Buyers should verify the original packaging, batch number, expiration date, product identity, and available manufacturer authentication features.

The standard REJURAN Healer presentation is 2 mL × 2 syringes per box. Individual-syringe sales or distributor bundles should not be confused with the original manufacturer packaging.

Storage & Handling

PharmaResearch specifies room-temperature storage between 1°C and 30°C for the original REJURAN formulation.

The product should be protected from light and maintained according to the original manufacturer-issued labeling.

• Storage Temperature: Store unopened syringes between 1°C and 30°C.
• Light Protection: Protect the product from direct light.
• Original Packaging: Maintain the syringes in their original manufacturer packaging.
• Sterile Barrier Integrity: Do not use products with damaged packaging or evidence of compromised sterility.
• Single-Patient Use: Follow the manufacturer's instructions regarding sterile handling and disposal.
• Product Traceability: Verify the product name, batch number, expiration date, and manufacturer authentication features.

Shelf Life

Manufacturer-associated product documentation identifies a shelf life of 24 months for the original REJURAN formulation.

The expiration date on the supplied product and its current manufacturer-issued instructions for use take precedence over general catalogue information.

REJURAN Healer's documented 1–30°C storage conditions should not be confused with the refrigerated storage requirements of REJURAN HB Plus. Always follow the original labeling of the exact supplied product.

Safety & Regulatory Considerations

REJURAN Healer is an injectable medical device intended for use by appropriately qualified healthcare professionals.

Clinical use requires consideration of the patient's medical history, known allergies, treatment-area characteristics, contraindications, and possible complications.

Potential Adverse Reactions

Potential adverse reactions associated with PN injections include localized pain, redness, swelling, bruising, tenderness, and temporary skin irregularities at the administration site.

Other possible complications include infection, hypersensitivity reactions, inflammatory responses, and persistent nodules.

The frequency and severity of these reactions may vary according to individual patient characteristics and the circumstances of administration.

Salmon-Derived Ingredient Considerations

REJURAN Healer contains polynucleotides derived from salmon DNA.

Patients with relevant hypersensitivity histories, including known reactions to fish-derived materials or formulation components, require appropriate clinical evaluation.

A manufacturer's purification process does not establish that hypersensitivity reactions are impossible.

Vascular Complications

Accidental introduction of injectable material into a blood vessel can cause serious complications.

Potential vascular injuries include compromised tissue perfusion, ischemia, and necrosis.

The original manufacturer-issued instructions for use should be followed regarding administration precautions and prohibited anatomical or vascular applications.

Contraindications and Precautions

Relevant contraindications and precautions include hypersensitivity to the formulation, active infection or inflammation in the intended treatment area, and certain medical conditions affecting treatment suitability.

Patients receiving anticoagulant, antiplatelet, anti-inflammatory, or immunosuppressive medicines may require additional clinical assessment according to the applicable product instructions.

The safety of treatment during pregnancy, breastfeeding, and in pediatric patients must be evaluated according to the original authorized labeling.

The manufacturer's instructions also contain precautions concerning certain previously treated areas and individuals with a tendency toward abnormal scarring.

South Korean Medical Device Authorization

The original REJURAN medical device family received South Korean authorization in April 2014 under MFDS permit number 14-825.

The registered product is classified as a Class IV tissue-restoration biomaterial.

Its documented intended purpose is the temporary improvement of facial wrinkles in adults.

The term Healer is widely used as the commercial designation for the original REJURAN formulation. Buyers should verify that the supplied product corresponds to the appropriate registered model and current labeling.

International Regulatory Authorization

PharmaResearch distributes REJURAN internationally through authorized medical aesthetics channels.

Regulatory authorization remains specific to each product, formulation, indication, and destination country.

US FDA approval for injectable REJURAN Healer has not been established.

The international availability of REJURAN and the existence of REJURAN-branded cosmetic skincare products do not automatically establish authorization for injectable use in the United States.

Professional buyers should verify the exact product registration, approved intended use, import eligibility, and lawful distribution requirements applicable to their market.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish individual patient suitability, or authorize use outside applicable medical device regulations.

Frequently Asked Questions